Midazolam Alone
Phase 2Small molecule
Midazolam Alone is one of 32 small molecule programs targeting Sedation. It is currently in Phase 2.
2
Indications
4
Total Trials
1
Active Trials
31
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
219 competitors in Cataract
#DrugCompanyPhaseTrials
1Lotemax
BBausch & Lomb Incorporated
Phase 3
Dexamethasone Phosphate
EEyegate Pharmaceuticals, Inc.
Phase 3
Ripasudil
KKowa Research Institute, Inc.
Phase 3
OCS-01
QQuan Dong Nguyen
Phase 3
Idose TR
GGlaukos Corporation
Phase 3
XG-102
XXigen SA
Phase 3
Midalozam
Idorsia Pharmaceuticals Ltd.Phase 3
Zolymbus
AbbViePreclinical
Neurontin
VViatris Specialty LLC
Preclinical
Midazolam Alone
MMelt Pharmaceuticals
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Midazolam Alone. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- MMelt Pharmaceuticals